Prakt. lékáren. 2012; 8(4): 170-174

Perspectives in the group of addictive substances

Martin Doležal
Katedra farmaceutické chemie a kontroly léčiv, Farmaceutická fakulta v Hradci Králové, Univerzita Karlova v Praze

Addictive substances have been with mankind from time immemorial, and their consumption and popularity has been increasing

worldwide. The review article presents their classification and the major groups of psychotropic compounds are discussed from

a pharmaceutical-chemical perspective. The study of relationships between the structure and biological effects in the group of plant,

endogenous, and synthetic cannabinoids and/or other compounds affecting the cannabinoid system in the brain is an important source

of both new medications and molecules that can be abused. The group of amphetamines, tryptamines, and other addictive substances

is presented in a similar way. Selected chemical structures are also mentioned. The aim of this paper is not and cannot be a complete

overview of all addictive substances of natural and synthetic origin; pharmacists and other health care professionals are fairly familiar

with most of them. In particular, the reader should obtain information on the current situation in the group of addictive substances.

Keywords: opiates, cannabinoids, amphetamines, tryptamines, designer drugs

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležal M. Perspectives in the group of addictive substances. Praktické lékárenství. 2012;8(4):170-174.
Download citation

References

  1. Sbírka zákonů č. 106/2011, zákon ze dne 6. dubna 2011, kterým se mění zákon č. 167/1998 S., o návykových látkách a o změně některých dalších zákonů, ve znění pozdějších předpisů.
  2. Nichols DE. CNS Stimulants. s. 89-120; McCurdy CR, Prisinzano TE. Opioid Receptor ligands. s. 569-735. In: Burger's Medicinal Chemistry, Drug Discovery and Development. Abraham DJ, Rotella DP. (Eds.). 7th ed., 2010, New York: Wiley, vol. 8 CNS Disorders.
  3. World Drug Report 2011, United Nations Office on Drugs and Crime. http://www.unodc.org/documents/data-andanalysis/WDR2011/World_Drug_Report_2011_ebook.pdf (datum přistoupení 21. května 2012).
  4. Galloway GP, Frederick-Osborne SL, Seymour R, Contini SE, Smith DE. Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 2000; 20: 263-269. Go to original source... Go to PubMed...
  5. Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P. The clinical toxicology of the designer, ,party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Phila) 2011; 49: 131-141. Go to original source... Go to PubMed...
  6. Devane WA, Hanuš L, Breuer A, a kol. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949. Go to original source... Go to PubMed...
  7. Hanuš LO. Bude konopí legálním lékem? Příspěvky české vědy do výzkumu konopí. Adiktologie 2004; 4: 511-523.
  8. Fišar Z. Endokanabinoidy. Chem Listy 2006; 100: 314-322.
  9. Synthetic cannabinoids in herbal products. United Nations Office on Drugs and Crime. http://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf (datum přistoupení 21. května 2012).
  10. Siebert DJ. Salvia Divinorum and Salvinorin A - New pharmacological findings. J Ethnopharmacol 1994; 43: 53-56. Go to original source... Go to PubMed...
  11. Národní monitorovací středisko pro drogy a drogové závislosti http://www.drogy-info.cz/(datum přistoupení 21. května 2012).
  12. Stanley TH, Egan TD, Aken HV. A Tribute to Dr. Paul A. J. Janssen: Entrepreneur Extraordinaire, Innovative Scientist, and Significant Contributor to Anesteziology. Anesth Analg 2008; 106: 451-462. Go to original source... Go to PubMed...
  13. Freeman S, Alder JF. Arylethylamine psychotropic recreational drugs: a chemical perspective. Eur J Med Chem 2002; 37: 527-539. Go to original source... Go to PubMed...
  14. Shulgin A, Shulgin A. PIHKAL, Phenethylamines I Have Known and Loved. Transform Press, Berkeley, USA, 1991.
  15. Shulgin A, Shulgin A. TIHKAL, Tryptamines I Have Known and Loved. Transform Press, Berkeley, USA, 1997.
  16. http://manatarka.biz/synthacaine (datum přistoupení 21. května 2012).
  17. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behavior Neurosci 2011; 5: 1-12. Go to original source... Go to PubMed...
  18. The Merck Index, 14th Edition, 2006 by Merck & Co., Inc., Whitehouse Station, ISBN 0-911 910-00-X, NJ, USA.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.